OUR PARTNERS

image66
image67

READDI: Creating Medicines for Future Pandemics

ABOUT READDI

THE NEED

PREPARING FOR THE FUTURE

PREPARING FOR THE FUTURE

The rapid emergence of viruses has caused widespread pandemics. This is exemplified by COVID-19, which has caught public health communities unprepared with no viable therapeutic treatments.

  • The unchecked spread of the disease has already resulted in more than a million people infected and nearly 70,000 deaths worldwide, as well as massive strains on health care infrastructure and the economy.
  • As outlined in a recent Nature article, experts agree on the need to radically rethink the clinical development process for pandemics. “...it is becoming increasingly clear that the biggest problem for drug and vaccine makers is not which therapeutic or vaccine platform to pursue. It is that conventional clinical development paths are far too lengthy and cumbersome to address the current public health threat.”
  • A new approach to the drug discovery and development process is needed in order to develop antiviral therapies before an epidemic begins.

PREPARING FOR THE FUTURE

PREPARING FOR THE FUTURE

PREPARING FOR THE FUTURE

READDI is retooling the drug discovery and development process to rapidly develop new antiviral drug solutions for future. These pandemics are bigger than any one company, government or academy. A unique public-private partnership accelerated by open science, READDI has a goal of developing multiple “on the shelf” clinical assets so that we are prepared for the next global health pandemic.

  • The science behind READDI focuses targeting cellular changes (kinase inhibitors) that block the replication of the virus. This work has been more than a year in the making.
  • READDI will focus on three viral families (coronavirus, flavivirus and alphavirus) that cause the vast majority of epidemics and pandemics. Our goal is to jumpstart antiviral drug development for rapidly emerging new viruses, even before the virus emerges.
  • READDI projects will adopt open science methods—sharing progress in real time to accelerate the pace of discovery so that all can benefit.

PHILANTHROPIC INVESTMENT

PHILANTHROPIC INVESTMENT

PHILANTHROPIC INVESTMENT

READDI aims to raise $125 million to generate 5 new drugs with human safety and dosing data (up to Phase 2 clinical trials) in 5 years to be ready for the next pandemic. This philanthropic investment will enable the world’s top researchers to work together to unlock effective therapeutic options so we are never caught off-guard again.

WHY READDI?

PHILANTHROPIC INVESTMENT

PHILANTHROPIC INVESTMENT

READDI brings together leaders from industry, government, philanthropic organizations and academic research institutions to leverage existing platforms and accelerate the development of new antiviral drugs.

  • A co-founder of READDI, the Structural Genomics Consortium is driving a new scientific and drug discovery ecosystem by focusing explicitly on less well-studies areas of the human genome. The SGC has partnerships with 9 global pharmaceutical companies and collaborations with scientists in hundreds of universities globally.
  • A co-founder of READDI, UNC-Chapel Hill ranks 8th among more than 25,000 institutions worldwide in coronavirus and 5th in the nation in federal research funding. According to US News & World Report, the UNC Eshelman School of Pharmacy is 1st in the nation and the UNC Gillings School of Global Public Health is 2nd in the nation. The UNC School of Medicine brings more than two decades of virology expertise to the initiative.
  • READDI was modeled after DNDi, an existing model for non-profit drug research and development. READDI is actively discussing partnership with leading academic institutions including University of Washington and UCSF. Additionally, pharmaceutical partners have already made initial commitments of financial and in-kind resources.
  • The open science model promotes faster drug discovery, bringing potentially life-saving drugs to market sooner and more cheaply.

RECENT PRESS RELEASES

CONTACT US

John Bamforth

John Bamforth

John Bamforth

Aled Edwards

John Bamforth

John Bamforth